COLUMBUS, Ohio — Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has successfully manufactured a novel viral vector gene therapy with its AAV Curator® Platform to treat a baby with the ultra-rare disease Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures...
Latest News
COLUMBUS, Ohio — Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Tern Therapeutics (Tern) to perform late-stage Process Performance Qualification (PPQ) manufacturing of Tern’s TTX-381 program. TTX-381 is an investigational gene therapy targeting vision loss in children with CLN2...
COLUMBUS, Ohio — Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced that it has been selected by Ultragenyx to perform late-stage Process Performance Qualification (PPQ) manufacturing of the company’s UX111 gene therapy for the potential treatment of Sanfilippo Syndrome (MPS...
WESTLAKE VILLAGE, Calif. — Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced that data from its ongoing program evaluating AGA2115 for the treatment of osteogenesis imperfecta (OI) will be presented at the American Society for Bone and...
GUILDFORD, SURREY – ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce breakthrough results from DNA molecular analysis of cancer patient blood samples that provide a unique insight into the progression...
GUILDFORD, UK – ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of new data from a proof-of-concept study in glioblastoma at the 7th Advances in Circulating Tumour Cells...
Its emerging rare disease unit is driving sales growth for ANI Pharmaceuticals Inc. Looking ahead the company wants to build and expand rare disease drug sales. “The first imperative is scaling up our rare disease business,” said Nikhil Lalwani, chief executive of ANI, in a morning earnings conference call with...
SAN JOSE, Calif. — Anixa Biosciences, Inc., a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application titled “Ovarian Cancer Vaccines.” Anixa Chairman and CEO Dr....
SAN JOSE, Calif. — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on its ovarian cancer CAR-T therapy clinical trial at the International Gynecologic Cancer Society (IGCS) 2024 Annual Global Meeting being held October 16-18, 2024, in Dublin,...
BOSTON, Mass. – Today at ACP’s annual meeting, v 2024, Annals of Internal Medicine presented three breaking scientific research articles during a live scientific plenary session that featured the authors of those articles. The articles were published in ACP’s flagship journal concurrent with the live meeting presentation. During the session,...